TapImmune Inc. Stock OTC Bulletin Board
Stocks
TPIV
US8760334081
Biotechnology & Medical Research
| Market Cap | 21.68M 18.7M 17.59M 16.02M 30.13M 2.06B 30.29M 208M 80.93M 1.05B 81.38M 79.61M 3.47B | P/E 2026 * |
-2.19x | P/E 2027 * | -1.48x |
|---|---|---|---|---|---|
| Enterprise Value | 21.68M 18.7M 17.59M 16.02M 30.13M 2.06B 30.29M 208M 80.93M 1.05B 81.38M 79.61M 3.47B | EV / Sales 2026 * |
5.11x | EV / Sales 2027 * | 1.07x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : TapImmune Inc.
| 21/08/21 | Wall Street hoger gesloten | |
| 21/08/21 | Wall Street koerst af op hoger slot | |
| 20/08/21 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 01/05/2023 |
| Chief Operating Officer | 36 | 01/12/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 17/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 24/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 06/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 22.18M | |
| +0.21% | -2.69% | +1.19% | +17.32% | 49.81B | |
| +2.09% | -0.71% | +452.73% | +498.77% | 44.06B | |
| -1.09% | -0.41% | +35.40% | +15.17% | 42.99B | |
| -0.26% | -4.71% | +17.19% | +71.67% | 40.88B | |
| -0.48% | -0.84% | +16.25% | +49.80% | 33.11B | |
| -1.81% | -5.02% | +22.65% | +113.24% | 16.58B | |
| -1.06% | +2.87% | - | - | 17.27B | |
| -1.35% | -3.40% | +10.13% | +26.34% | 14.63B | |
| -2.05% | -5.14% | +72.89% | +34.69% | 13.76B | |
| Average | -0.74% | -1.84% | +78.55% | +103.38% | 30.34B | |
| Weighted average by Cap. | -0.51% | -1.75% | +94.97% | +120.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.24M 3.66M 3.44M 3.14M 5.9M 403M 5.93M 40.69M 15.84M 205M 15.93M 15.58M 679M | 20.19M 17.41M 16.38M 14.92M 28.06M 1.92B 28.21M 194M 75.37M 975M 75.79M 74.14M 3.23B |
| Net income | -11.84M -10.21M -9.6M -8.75M -16.45M -1.12B -16.54M -114M -44.19M -571M -44.44M -43.48M -1.89B | -18.09M -15.61M -14.68M -13.37M -25.15M -1.72B -25.28M -174M -67.55M -873M -67.93M -66.45M -2.9B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
